Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
This is a blood collection study being conducted to better understand and describe the immunological blood profile changes in patients with advanced non small cell lung cancer undergoing treatment with checkpoint inhibitor therapy. Blood will be collected from healthy volunteers and patients with non small cell lung cancer
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 20, 2022 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Indiana University
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. ≥ 18 years old at the time of informed consent 2. Written informed consent and HIPAA authorization for release of personal health information. 3. Subjects with histologically and radiographically confirmed NSCLC. 4. Subjects must have stage IV disease or recurrent disease. 5. Subjects should be treatment naïve (systemic therapies) or have received prior chemotherapy in the first line setting. Prior radiation or surgery is permissible. 6. Subjects who are eligible to receive single agent immunotherapy must have documentation of a PD-L1 Tumor Proportion Score (TPS) of at least 1%. 7. Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
1. Subjects with curable or potentially curable NSCLC. 2. Subjects should not have contraindications to treatment with immune checkpoint inhibitors per standard criteria. 3. Patients with targetable mutations eligible for treatment with molecularly targeted small molecule inhibitor therapy. 4. Subjects eligible for combination treatment with chemoimmunotherapy.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Indiana University Melvin & Bren Simon Cancer CenterIndianapolis, Indiana
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 20, 2022. Always confirm current availability with the study team.